Similarly, a few clinical studies have reported that a dramatic decline in serum GH/IGF-1 levels in patients with AD and subsequent IGF-1 administration could provide significant benefits to these patients [24, 40]. The gene discussed is GH1; the disease is Alzheimer disease.